This Week in Pulmonary — Aug 4, 2026

Welcome to This Week in Pulmonary. This week we are covering ten notable papers spanning innovations in acute care oxygenation and sepsis phenotypes, optimization strategies in chronic airway and interstitial diseases, and new insights into pulmonary vascular and sleep medicine. Let us dive in.

We begin in the intensive care unit, where two studies offer new ways to personalize and automate our care for critically ill patients. First, a major randomized clinical trial published in JAMA Internal Medicine evaluated the clinical utility of autonomous oxygen titration [1]. In standard practice, busy clinicians titrate supplemental oxygen intermittently, which frequently leaves hospitalized patients drifting into periods of hypoxemia or hyperoxemia. To address this, investigators conducted a multicenter, unblinded trial across four United States hospitals, randomizing three hundred acutely ill adults to receive either autonomous oxygen titration or usual manual care during their first seventy-two hours of supplemental oxygen therapy. The results were striking. Patients in the autonomous group spent eighty-five percent of their time in the targeted normoxemia range of ninety to ninety-six percent oxygen saturation, compared to just sixty-three percent in the usual care group. This represents an absolute increase of twenty-one percentage points. Furthermore, autonomous titration cut the time spent in deep hypoxemia nearly in half, from three point six percent down to two percent, and dramatically reduced exposure to hyperoxemia from twenty-nine percent to just over nine percent. These findings suggest that implementing closed-loop oxygen systems can significantly improve oxygenation safety and precision in acute care settings. Moving from automated oxygenation to precision medicine in infection, a study in the American Journal of Respiratory and Critical Care Medicine sought to better characterize inflammatory phenotypes in severe pneumonia [3]. Researchers performed a latent class analysis on a cohort of five hundred and forty-eight critically ill patients with pulmonary sepsis, identifying two distinct clinical phenotypes: a hyperinflammatory phenotype characterized by severe lung injury and higher mortality, and a hypoinflammatory phenotype with more favorable outcomes. To test targeted therapies, the investigators successfully established a translational mouse model of pneumococcal pneumonia that mirrored these exact human phenotypes. Crucially, when they administered anti-inflammatory therapies, specifically dexamethasone and interleukin-six receptor blockade, therapeutic benefit was observed exclusively in the hyperinflammatory cohort, while the hypoinflammatory group saw no benefit. This translational framework strongly suggests that future clinical trials for severe pneumonia should select patients based on inflammatory biomarkers rather than treating all cases of pulmonary sepsis uniformly.

Next, we turn to chronic airway management, where several new studies highlight how we can better balance treatment efficacy and safety. A large, population-based case-control study published in Thorax raises important safety considerations regarding corticosteroid use and the risk of pulmonary aspergillosis [2]. Examining data from over thirteen hundred Danish patients with non-allergic bronchopulmonary aspergillosis, researchers found a strong, dose-dependent association with both inhaled and systemic corticosteroids. For patients using inhaled corticosteroids, the risk of developing aspergillosis was nearly tripled at daily doses exceeding six hundred and forty micrograms, while even lower doses increased the risk by seventy percent. Oral corticosteroids carried an even higher risk, with doses over five point six milligrams daily associated with a four-fold increase in aspergillosis. This risk was found to decrease as time elapsed since the last exposure. This serves as a powerful reminder of the importance of maintaining patients on the lowest effective dose of corticosteroids to minimize serious infectious complications. Fortunately, the rise of biologic therapies is making corticosteroid de-escalation far more feasible. A real-world retrospective study published in Respiratory Medicine evaluated the safety of de-escalating maintenance therapies in fifty-four patients with severe T2-high asthma who were well-controlled on dupilumab [7]. Over an eighteen-month follow-up, clinicians successfully reduced the proportion of patients requiring high-dose inhaled corticosteroids from eighty-five percent down to forty-seven percent, alongside similar de-escalations in long-acting muscarinic antagonists and leukotriene receptor antagonists. Importantly, patients who underwent maintenance therapy de-escalation experienced no clinical deterioration, and their rates of clinical remission, lung function, and asthma control remained identical to those who continued full-strength maintenance therapy. This provides reassuring real-world evidence that we can safely step down inhaled therapies once biologic control is established. In the same journal, researchers explored another common cause of expiratory airflow limitation that is often misdiagnosed as refractory asthma or chronic obstructive pulmonary disease: dynamic airway collapse and tracheobronchomalacia [9]. In a prospective cohort of seventy-four patients undergoing dynamic flexible bronchoscopy, investigators challenged the traditional fifty percent airway lumen reduction threshold used for diagnosis, arguing it lacks clinical specificity. Instead, they found that a seventy percent collapse threshold better identified patients with clinically significant disease. Interestingly, nearly sixty percent of patients with significant airway collapse had entirely normal spirometry, highlighting why this condition is so frequently overlooked. Higher degrees of collapse were significantly associated with elevated body mass index and the initiation of continuous positive pressure therapy, which led to clinical improvement in almost eighty-eight percent of those treated. The study proposes a structured, severity-based diagnostic and therapeutic algorithm to help clinicians identify and manage these patients more systematically. Meanwhile, for our younger patients with cystic fibrosis, a longitudinal study in Respiratory Medicine investigated the real-world efficacy and heterogeneity of elexacaftor-tezacaftor-ivacaftor in seventy children aged six to eleven [10]. At one year of therapy, the overall cohort experienced significant improvements in lung function, with an average increase in percent predicted forced expiratory volume in one second of nearly five percent, alongside a mean body mass index increase of zero point six-eight kilograms per square meter. However, when looking closer at the subgroups, these physiological improvements were primarily concentrated in children who were homozygous for the F508del mutation, those who were naive to prior modulator therapies, and those starting with worse baseline lung function. Reassuringly, the entire cohort, regardless of subgroup, experienced significant reductions in pulmonary exacerbations, hospitalizations, and the need for daily supportive therapies like dornase alfa and hypertonic saline, confirming the profound real-world benefit of triple-combination therapy in this younger population.

Our final theme explores the complex intersection of pulmonary pathology with cardiovascular, interstitial, and sleep disorders. We begin with a prospective cohort study in Chest that offers a highly practical clinical insight for managing obstructive sleep apnea [5]. It is well established that comorbid insomnia and sleep apnea, often referred to as COMISA, is associated with poor blood pressure control. In this study, seventy-one adults with sleep apnea and elevated blood pressure underwent four weeks of auto-CPAP therapy. When stratified, the comorbid insomnia group achieved a highly significant mean reduction in twenty-four-hour systolic blood pressure of six millimeters of mercury, compared to a negligible reduction of less than one millimeter of mercury in the apnea-only group. After adjusting for potential confounders, the presence of insomnia symptoms was associated with a more than five-fold increase in the odds of achieving a clinically meaningful blood pressure reduction of five millimeters of mercury or more. This suggests that patients with comorbid insomnia represent a specific phenotype that stands to gain immense cardiovascular benefit from CPAP, highlighting the clinical importance of aggressively treating both sleep disorders and supporting CPAP adherence in this population. In the realm of pulmonary vascular disease, the RIVER Two study published in Respiratory Research evaluated the effects of the soluble guanylate cyclase stimulator, riociguat, on right ventricular remodeling in thirty patients with pulmonary arterial hypertension [6]. Over twenty-four weeks, riociguat therapy led to a significant reduction in both right atrial and right ventricular areas, with concurrent improvements in right ventricular fractional area change, six-minute walk distance, and WHO functional class. In patients who underwent invasive follow-up, cardiac index also improved significantly. These prospective findings confirm that riociguat can actively promote favorable reverse remodeling of the right heart, which is a critical determinant of long-term prognosis in pulmonary arterial hypertension. Turning to interstitial lung disease, a large population-based study in Respiratory Medicine evaluated the survival impact of comorbid obstructive lung disease in over six thousand patients with rheumatoid arthritis-associated interstitial lung disease [8]. The researchers found that an astonishing sixty-eight percent of these patients carried a comorbid diagnosis of obstructive lung disease. Crucially, the presence of chronic obstructive pulmonary disease or asthma-COPD overlap was associated with a significant increase in mortality compared to having interstitial disease alone or interstitial disease with asthma. This underscores the profound survival disadvantage conferred by comorbid airway obstruction in rheumatoid arthritis patients, emphasizing the need for vigilant screening and targeted management of airflow limitation in this vulnerable population. Finally, we look at patient-reported outcomes in thoracic oncology from the NRG Oncology Alliance LU zero-zero-five trial, published in the Journal of Thoracic Oncology [4]. This trial randomized five hundred and forty-four patients with limited-stage small cell lung cancer to chemoradiation with or without the immunotherapy agent atezolizumab. While the addition of atezolizumab did not improve overall survival, this planned secondary analysis focused on long-term quality of life using validated patient-reported outcome instruments. The addition of atezolizumab did not result in any significant differences in clinically meaningful decline in quality of life or fatigue scores at fifteen months. Interestingly, although patients were not randomized to their radiation schedule, those who received twice-daily radiation therapy demonstrated a consistently more favorable quality of life trajectory across all timepoints compared to those receiving once-daily radiation. This suggests that twice-daily radiation may offer a more tolerable course for patients undergoing concurrent chemoradiation.

If you only have time for one paper this week, make it the SAVE-O2 AI randomized clinical trial published in JAMA Internal Medicine [1]. This study provides high-quality, multicenter evidence that autonomous closed-loop oxygen titration dramatically improves the time patients spend in safe normoxemic ranges while reducing dangerous exposure to both hypoxemia and hyperoxemia. As we look to modernize inpatient care, this technology represents a highly practical and scalable way to improve patient safety and reduce the clinical burden of manual oxygen titration.

Here are the key takeaways from this week in Pulmonary. First, automated, closed-loop oxygen titration systems can significantly increase the time hospitalized patients spend in safe normoxemic ranges, cutting the risk of both hypoxemia and hyperoxemia. Second, both inhaled and oral corticosteroids carry a significant, dose-dependent risk of pulmonary aspergillosis, reinforcing the clinical mandate to use the lowest effective dose for chronic airway diseases. Third, in patients with severe T2-high asthma who are well-controlled on dupilumab, we can safely de-escalate high-dose inhaled corticosteroids and other controller therapies without risking clinical deterioration. Fourth, when treating obstructive sleep apnea, the presence of comorbid insomnia identifies a patient phenotype that experiences a highly pronounced, clinically meaningful blood pressure reduction in response to CPAP therapy. And finally, comorbid chronic obstructive pulmonary disease is highly prevalent in patients with rheumatoid arthritis-associated interstitial lung disease and is associated with a significant increase in mortality, making early identification and management of airway obstruction critical.

That is your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.